MorphoSys Corporate Presentation 2023

MorphoSys presented its strategic oncology focus and pipeline, including Monjuvi (tafasitamab) for relapsed/refractory DLBCL and investigational programs in solid tumors, lymphomas, and myelofibrosis. The company highlighted strong cash runway extending into 2025 and outlined ambitions to redefine cancer treatment through clinical development and regulatory expansion.